Table 3.
Comparison between preclinical in vivo doses of NOTCH-targeted agents used for non-small cell lung cancer treatment.
| Treatment | Preclinical dose | Reference | |
|---|---|---|---|
| Type | Name | ||
| GSI | DAPT | 8 mg/kg ip 3 days/week or l0 mg/kg ip once every 3 days * 6 injections | (130, 159) |
| MRK-003 | 150 mg/kg 3 days/week | (160) | |
| BMS-708163 | 10 mg/kg po 5 days/week | (162) | |
| LY-411575 | 3 mg/kg po daily | (164) | |
| GSI XX | 200 µg/kg ip 3 days/week * 2 cycles | (165) | |
| GSI? | 200 µg/kg ip 3 days/week * 2 cycles | (166) | |
| mAb | CT16 (anti-EGFR and anti-NOTCH 2/3) | 40 mg/kg | (131) |
| Tarextumab (anti-NOTCH 2/3) | 40 mg/kg | (131) | |
| HD105 (anti-DLL 4 and anti-VEGF) | 3.25 mg/kg ip 1–2 days/week or 6.5 mg/kg ip 1 day/week | (148) | |
| Murine anti-DLL4 | 2.5 mg/kg ip 1–2 days/week | (148) | |
| Demcizumab (anti-DLL4) | 10 mg/kg ip 1 day/week | (164) | |
GSI, gamma-secretase inhibitor; mAb, monoclonal antibody; ip, intraperitoneal; po, per os (oral administration).